Cell Death and Senescence-Based Molecular Classification and an Individualized Prediction Model for Lung Adenocarcinoma

Abstract

The exploration of cell death and cellular senescence (CDS) in cancer has been an area of interest, yet a systematic evaluation of CDS features and their interactions in lung adenocarcinoma (LUAD) to understand tumor heterogeneity, tumor microenvironment (TME) characteristics, and patient clinical outcomes is previously uncharted. Our study characterized the activities and interconnections of 21 CDS features in 1788 LUAD cases across 15 cohorts, employing unsupervised clustering to categorize patients into three CDS subtypes with distinct TME profiles. The CDS index (CDSI), derived from principal component analysis, was developed to assess individual tumor CDS regulation patterns. Twelve CDSI core genes, enriched in proliferating T cells within the TME as per single-cell analysis, were identified and their functional roles and prognostic significance were validated. High CDSI correlated with improved overall survival in discovery cohort, four independent validation cohorts, and subgroup analysis. CDSI-low patients exhibited a favorable clinical response to immunotherapy and potential sensitivity to mitosis pathway drugs, while CDSI-high patients might benefit from drugs targeting ERK/MAPK and MDM2–p53 pathways. The clinical utility of CDSI was further validated using 9185 pan-cancer samples, demonstrating the broad relevance of our prediction model across various cancer types and its potential clinical implications for cancer management.

Keywords

cancer subtype / cellular senescence / cell death / lung adenocarcinoma / tumor microenvironment

References

[1] W. Cao, H. D. Chen, Y. W. Yu, N. Li, and W. Q. Chen, “Changing Profiles of Cancer Burden Worldwide And in China: A Secondary Analysis of the Global Cancer Statistics 2020,” Chinese Medical Journal 134, no. 7 (2021): 783-791.

[2] J. A. Barta, C. A. Powell, and J. P. Wisnivesky, “Global Epidemiology of Lung Cancer,” Annals of Global Health 85, no. 1 (2019).

[3] E. L. Schenk, T. Patil, and J. Pacheco, “2020 Innovation-Based Optimism for Lung Cancer Outcomes,” The Oncologist 26, no. 3 (2021): e454-e472.

[4] L. Horvath, B. Thienpont, L. Zhao, D. Wolf, and A. Pircher, “Overcoming Immunotherapy Resistance in Non-Small Cell Lung Cancer (NSCLC)—Novel Approaches and Future Outlook,” Molecular cancer 19, no. 1 (2020): 141.

[5] M. Suzanne and H. Steller, “Shaping Organisms With Apoptosis,” Cell Death and Differentiation 20, no. 5 (2013): 669-675.

[6] T. Vanden Berghe, A. Linkermann, S. Jouan-Lanhouet, H. Walczak, and P. Vandenabeele, “Regulated Necrosis: The Expanding Network of Non-Apoptotic Cell Death Pathways,” Nature Reviews Molecular Cell Biology 15, no. 2 (2014): 135-147.

[7] L. Galluzzi, I. Vitale, S. A. Aaronson, et al., “Molecular Mechanisms of Cell Death: Recommendations of the Nomenclature Committee on Cell Death 2018,” Cell Death and Differentiation 25, no. 3 (2018): 486-541.

[8] S. Bedoui, M. J. Herold, and A. Strasser, “Emerging Connectivity of Programmed Cell Death Pathways and its Physiological Implications,” Nature Reviews Molecular Cell Biology 21, no. 11 (2020): 678-695.

[9] G. Kroemer, C. Galassi, L. Zitvogel, and L. Galluzzi, “Immunogenic Cell Stress and Death,” Nature Immunology 23, no. 4 (2022): 487-500.

[10] E. Koren and Y. Fuchs, “Modes of Regulated Cell Death in Cancer,” Cancer discovery 11, no. 2 (2021): 245-265.

[11] V. Gorgoulis, P. D. Adams, A. Alimonti, et al., “Cellular Senescence: Defining a Path Forward,” Cell 179, no. 4 (2019): 813-827.

[12] E. Sikora, A. Bielak-Zmijewska, and G. Mosieniak, “A Common Signature of Cellular Senescence; does it exist?,” Ageing Research Reviews 71 (2021): 101458.

[13] D. Hanahan, “Hallmarks of Cancer: New Dimensions,” Cancer discovery 12, no. 1 (2022): 31-46.

[14] M. Fane and A. T. Weeraratna, “How the Ageing Microenvironment Influences Tumour Progression,” Nature Reviews Cancer 20, no. 2 (2020): 89-106.

[15] B. G. Childs, D. J. Baker, J. L. Kirkland, J. Campisi, and J. M. van Deursen, “Senescence and Apoptosis: Dueling or Complementary Cell Fates?,” Embo Reports 15, no. 11 (2014): 1139-1153.

[16] Y. Aman, T. Schmauck-Medina, M. Hansen, et al., “Autophagy in Healthy Aging and Disease,” Nature Aging 1, no. 8 (2021): 634-650.

[17] G. H. Royce, H. M. Brown-Borg, and S. S. Deepa, “The Potential Role of Necroptosis in Inflammaging and Aging,” Geroscience 41, no. 6 (2019): 795-811.

[18] Y. Qin, Y. Liu, X. Xiang, et al., “Cuproptosis Correlates With Immunosuppressive Tumor Microenvironment Based on Pan-cancer Multiomics and Single-Cell Sequencing Analysis,” Molecular cancer 22, no. 1 (2023): 59.

[19] Y. Zou, J. Xie, S. Zheng, et al., “Leveraging Diverse Cell-death Patterns to Predict the Prognosis and Drug Sensitivity of Triple-Negative Breast Cancer Patients After Surgery,” International Journal of Surgery 107 (2022): 106936.

[20] Y. Zhou, W. Gao, Y. Xu, et al., “Implications of Different Cell Death Patterns for Prognosis and Immunity in Lung Adenocarcinoma,” NPJ Precision Oncology 7, no. 1 (2023): 121.

[21] X. Wang, L. Ma, X. Pei, et al., “Comprehensive Assessment of Cellular Senescence in the Tumor Microenvironment,” Briefings in Bioinformatics 23, no. 3 (2022).

[22] M. Y. Lv, D. Cai, C. H. Li, et al., “Senescence-based Colorectal Cancer Subtyping Reveals Distinct Molecular Characteristics and Therapeutic Strategies,” MedComm 4, no. 4 (2023): e333.

[23] V. Thorsson, D. L. Gibbs, S. D. Brown, et al., “The Immune Landscape of Cancer,” Immunity 48, no. 4 (2018): 812-830.

[24] A. Bagaev, N. Kotlov, K. Nomie, et al., “Conserved Pan-cancer Microenvironment Subtypes Predict Response to Immunotherapy,” Cancer Cell 39, no. 6 (2021): 845-865. e847.

[25] Y. Zhou, B. Zhou, L. Pache, et al., “Metascape Provides a Biologist-Oriented Resource for the Analysis of Systems-Level Datasets,” Nature Communications 10, no. 1 (2019): 1523.

[26] T. M. Malta, A. Sokolov, A. J. Gentles, et al., “Machine Learning Identifies Stemness Features Associated With Oncogenic Dedifferentiation,” Cell 173, no. 2 (2018): 338-354. e315.

[27] R. M. Meyers, J. G. Bryan, J. M. McFarland, et al., “Computational Correction of Copy Number Effect Improves Specificity of CRISPR-Cas9 Essentiality Screens in Cancer Cells,” Nature Genetics 49, no. 12 (2017): 1779-1784.

[28] F. M. Behan, F. Iorio, G. Picco, et al., “Prioritization of Cancer Therapeutic Targets Using CRISPR-Cas9 Screens,” Nature 568, no. 7753 (2019): 511-516.

[29] D. Szklarczyk, A. L. Gable, K. C. Nastou, et al., “The STRING Database in 2021: Customizable Protein-Protein Networks, and Functional Characterization of User-uploaded Gene/measurement Sets,” Nucleic Acids Research. 49, no. D1 (2021): D605-D612.

[30] G. Yu, F. Li, Y. Qin, X. Bo, Y. Wu, and S. Wang, “GOSemSim: An R Package for Measuring Semantic Similarity Among GO Terms and Gene Products,” Bioinformatics 26, no. 7 (2010): 976-978.

[31] L. Zhu, D. Ye, T. Lei, J. Wu, W. Wang, and B. Xu, “Cancer Mutation Profiles Predict ICIs Efficacy in Patients With Non-Small Cell Lung Cancer,” Expert Reviews in Molecular Medicine 24 (2022): e16.

[32] M. Ayers, J. Lunceford, M. Nebozhyn, et al., “IFN-gamma-related mRNA Profile Predicts Clinical Response to PD-1 Blockade,” Journal of Clinical Investigation 127, no. 8 (2017): 2930-2940.

[33] W. Hugo, J. M. Zaretsky, L. Sun, et al., “Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma,” Cell 165, no. 1 (2016): 35-44.

[34] M. G. Rees, B. Seashore-Ludlow, J. H. Cheah, et al., “Correlating Chemical Sensitivity and Basal Gene Expression Reveals Mechanism of Action,” Nature Chemical Biology 12, no. 2 (2016): 109-116.

[35] S. M. Corsello, R. T. Nagari, R. D. Spangler, et al., “Discovering the Anti-Cancer Potential of Non-Oncology Drugs by Systematic Viability Profiling,” Nature Cancer 1, no. 2 (2020): 235-248.

[36] W. Yang, J. Soares, P. Greninger, et al., “Genomics of Drug Sensitivity in Cancer (GDSC): A Resource for Therapeutic Biomarker Discovery in Cancer Cells,” Nucleic Acids Research. 41 (2013): D955-961. Database issue.

[37] M. Zheng and T. D. Kanneganti, “The Regulation of the ZBP1-NLRP3 Inflammasome and Its Tmplications in Pyroptosis, Apoptosis, and Necroptosis (PANoptosis),” Immunological Reviews 297, no. 1 (2020): 26-38.

[38] Y. Tie, F. Tang, Y. Q. Wei, and X. W. Wei, “Immunosuppressive Cells in Cancer: Mechanisms and Potential Therapeutic Targets,” Journal of hematology & oncology 15, no. 1 (2022): 61.

[39] M. B. Buechler, R. N. Pradhan, A. T. Krishnamurty, et al., “Cross-Tissue Organization of the Fibroblast Lineage,” Nature 593, no. 7860 (2021): 575-579.

[40] P. M. Galbo, X. Zang, and D. Zheng, “Molecular Features of Cancer-associated Fibroblast Subtypes and heir Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance,” Clinical Cancer Research 27, no. 9 (2021): 2636-2647.

[41] C. Yang, Y. Guo, Z. Wu, J. Huang, and B. Xiang, “Comprehensive Analysis of Cuproptosis-Related Genes in Prognosis and Immune Infiltration of Hepatocellular Carcinoma Based on Bulk and Single-Cell RNA Sequencing Data,” Cancers (Basel) 14, no. 22 (2022).

[42] Y. Chen, Q. X. Lin, Y. T. Xu, et al., “An Anoikis-Related Gene Signature Predicts Prognosis and Reveals Immune Infiltration in Hepatocellular Darcinoma,” Frontiers in oncology 13 (2023): 1158605.

[43] H. Li, A. M. van der Leun, I. Yofe, et al., “Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment Within Human Melanoma,” Cell 176, no. 4 (2019): 775-789.

[44] J. Clarke, B. Panwar, A. Madrigal, et al., “Single-cell Transcriptomic Analysis of Tissue-resident Memory T Cells in Human Lung Cancer,” Journal of Experimental Medicine 216, no. 9 (2019): 2128-2149.

[45] M. Sade-Feldman, K. Yizhak, S. L. Bjorgaard, et al., “Defining T Cell States Associated With Response to Checkpoint Immunotherapy in Melanoma,” Cell 175, no. 4 (2018): 998-1013. e1020.

[46] S. Bin Lim, M. L. K. Chua, J. P. S. Yeong, S. J. Tan, W. T. Lim, and C. T. Lim, “Pan-Cancer Analysis Connects Tumor Matrisome to Immune rResponse,” NPJ Precision Oncology 3 (2019): 15.

[47] J. Chen, H. Yang, A. S. M. Teo, et al., “Genomic Landscape of Lung Adenocarcinoma in East Asians,” Nature Genetics 52, no. 2 (2020): 177-186.

[48] S. Mariathasan, S. J. Turley, D. Nickles, et al., “TGFbeta Attenuates Tumour Response to PD-L1 Blockade by Contributing to Exclusion of T cells,” Nature 554, no. 7693 (2018): 544-548.

[49] M. Ghandi, F. W. Huang, J. Jane-Valbuena, et al., “Next-Generation Characterization of the Cancer Cell Line Encyclopedia,” Nature 569, no. 7757 (2019): 503-508.

[50] N. Zhou and J. Bao, “FerrDb: A Manually Curated Resource for Regulators and Markers of Ferroptosis and Ferroptosis-Disease Associations,” Database (Oxford) 2020 (2020).

[51] S. Hanzelmann, R. Castelo, and J. Guinney, “GSVA: Gene Set Variation Analysis for Microarray and RNA-seq Data,” BMC Bioinformatics [Electronic Resource] 14 (2013): 7.

[52] M. D. Wilkerson and D. N. Hayes, “ConsensusClusterPlus: A Class Discovery Tool With Confidence Assessments and Item Tracking,” Bioinformatics 26, no. 12 (2010): 1572-1573.

[53] M. E. Ritchie, B. Phipson, D. Wu, et al., “Limma Powers Differential Expression Analyses for RNA-Sequencing and Microarray Studies,” Nucleic Acids Research. 43, no. 7 (2015): e47.

[54] Y. Jiang, A. Sun, Y. Zhao, et al., “Proteomics Identifies New Therapeutic Targets of Early-stage Hepatocellular Carcinoma,” Nature 567, no. 7747 (2019): 257-261.

[55] A. Subramanian, P. Tamayo, V. K. Mootha, et al., “Gene Set Enrichment Analysis: A Knowledge-Based Approach for Interpreting Genome-wide Expression Profiles,” Proceedings of the National Academy of S 102, no. 43 (2005): 15545-15550.

[56] B. Miron and W. R. R. Kursa, “Feature Selection With the Boruta Package,” Journal of Statistical Software 36, no. 11 (2010): 1-3.

[57] C. Sotiriou, P. Wirapati, S. Loi, et al., “Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade to Improve Prognosis,” JNCI: Journal of the National Cancer Institute 98, no. 4 (2006): 262-272.

[58] Y. Han, Y. Wang, X. Dong, et al., “TISCH2: Expanded Datasets and New Tools for Single-Cell Transcriptome Analyses of the Tumor Microenvironment,” Nucleic Acids Research. 51, no. D1 (2023): D1425-D1431.

[59] A. Mayakonda, D. C. Lin, Y. Assenov, C. Plass, and H. P. Koeffler, “Maftools: Efficient and Comprehensive Analysis of Somatic Variants In Cancer,” Genome Research 28, no. 11 (2018): 1747-1756.

[60] A. Colaprico, T. C. Silva, C. Olsen, et al., “TCGAbiolinks: An R/Bioconductor Package for Integrative Analysis of TCGA Data,” Nucleic Acids Research. 44, no. 8 (2016): e71.

[61] C. H. Mermel, S. E. Schumacher, B. Hill, M. L. Meyerson, R. Beroukhim, and G. Getz, “GISTIC2.0 Facilitates Sensitive and Confident Localization of the Targets of Focal Somatic Copy-Number Alteration in Human Cancers,” Genome biology 12, no. 4 (2011): R41.

[62] D. Maeser, R. F. Gruener, and R. S. Huang, “oncoPredict: An R Package for Predicting in vivo or Cancer Patient Drug Response and Biomarkers From Cell Line Screening Data,” Briefings in Bioinformatics 22, no. 6 (2021).

[63] C. Yang, X. Huang, Y. Li, J. Chen, Y. Lv, and S. Dai, “Prognosis and Personalized Treatment Prediction in TP53-Mutant Hepatocellular Carcinoma: An in Silico Strategy Towards Precision Oncology,” Briefings in Bioinformatics 22, no. 3 (2021).

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.